Research Article
Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops
Table 1
Patient characteristics in the tafluprost and DTFC treatment groups.
| | Tafluprost (33 eyes of 33 patients) | DTFC (33 eyes of 33 patients) | value |
| Mean age ± SD (years) | 53.6 ± 13.5 | 54.4 ± 12.2 | 0.768 | Sex (male : female) | 17 : 16 | 16 : 17 | 0.625 | SE (diopter) | −2.9 ± 4.3 | −2.4 ± 2.7 | 0.533 | Diagnosis (NTG : POAG) | 9 : 24 | 25 : 8 | <0.001 | CCT ± SD (μm) | 534.6 ± 33.9 | 545.2 ± 38.3 | 0.199 | Cup-to-disc ratio | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.853 | Pretreatment IOP (mmHg) | 18.91 ± 2.53 | 15.64 ± 1.77 | <0.001 | Posttreatment IOP (mmHg) | 14.18 ± 1.69 | 13.67 ± 2.73 | 0.338 | IOP reduction (%) | 25.0 | 12.6 | | Pretreatment OPA (mmHg) | 3.08 ± 0.74 | 2.26 ± 0.77 | <0.001 | Posttreatment OPA (mmHg) | 2.30 ± 0.74 | 2.03 ± 0.66 | 0.192 | OPA reduction (%) | 25.3 | 10.2 | | Pretreatment cOPA (mmHg) | 3.08 ± 0.74 | 2.26 ± 0.77 | <0.001 | Posttreatment cOPA (mmHg) | 1.99 ± 0.85 | 1.90 ± 0.75 | 0.748 | cOPA reduction (%) | 35.4 | 15.9 | | Baseline VF MD (decibel) | −9.4 ± 7.6 | −9.1 ± 5.7 | 0.909 | OCT cpRNFL thickness (micron) | 75.7 ± 17.2 | 76.4 ± 15.4 | 0.577 |
|
|
NTG: normal tension glaucoma; POAG: primary open angle glaucoma; SE: spherical equivalent; CCT: central corneal thickness; IOP: intraocular pressure; OPA: ocular pulse amplitude; cOPA: corrected OPA; VF MD: visual field mean deviation; OCT: optical coherence tomography; cpRNFL: circumpapillary retinal nerve fiber layer.
|